Evotaz (atazanavir;cobicistat)
- Region
- 🇪🇺 EU
- Active substance
- atazanavir;cobicistat
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 21 May 2015
- EU approval
- Mon 13 Jul 2015
- Application
- EMEA/H/C/003904
- ATC
- J05AR15
- Official record
- www.ema.europa.eu
Indication
EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Evotaz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.